$5.53
+11%OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
Chief Commercial Officer
Chief Financial Officer & Chief Operating Officer
Compensation
$578,479
Chief Legal Officer & Chief Human Resources Officer
Compensation
$428,117
Chief Product Officer & Chief Technology Officer
Controller
Human Resources Manager
Media Relations Manager
President & Chief Executive Officer
Compensation
$544,960
Senior Vice President of Corporate Finance
During the last 12 months, insiders have purchased $3.22M and sold $281K worth of OPRX shares, resulting in $2.93M of net buying activity.
0
0.00
0
0.00
+0
+$0
0
0.00
1.4K
18.75K
-19K
-$19K
0
0.00
0
0.00
+0
+$0
199.2K
3.22M
24.8K
262.42K
+3.0M
+$2.95M
Silvestro Stephen L
Officer: Chief Executive Officer
$567K
Odence-Ford Marion
Officer: Chief Legal & Admin Officer
$567K
Stelmakh Edward
Officer: Cfo/Coo
$567K
Besch Doug
Officer: Chief Prod & Tech Officer
$567K
Greco Theresa
Officer: Chief Commercial Officer
$567K
Spangler Patrick D
Director
$194K
D'Silva Andrew J.
Officer: Chief Business Officer
$68K
Stelmakh Edward
Officer: Chief Finance & Strat Officer
$19K
Strong bullish signal with $2.93M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
OPRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | July 08, 2021 | August 19, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 01, 2020 | November 19, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | September 24, 2019 | November 04, 2019 | 2019 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.